Among these biologic agents approved for the treatment of plaque psoriasis are the interleukin-17A (IL-17A) inhibitors, such as secukinumab and ixekizumab; both have demonstrated significant efficacy in terms of reduction in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) and have generally exhibited a favorable safety profile [6,7,8]. This evidence concerns the gene IL17A and psoriasis vulgaris.